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The Experts Advisory Committee on Immunization Program (EACIP) of China was founded in 1982, and
currently consists of 33 experts in immunization and related ﬁelds, selected by the Ministry of Health,
to provide advice and guidance on the control of vaccine-preventable diseases. The main tasks of the
EACIP are to advise on the national immunization schedule, to participate in the drafting and review of
technical documents, and to participate in ﬁeld supervision and staff training. In 2007, the EACIP used
evidence-based methods to formulate a revised national immunization schedule. The EACIP has played
nglyand is playing an increasi
. Background
China initiated the National Expanded Program on Immuniza-
ion (EPI) in 1978. The targeted children were vaccinated with
acillus Calmette-Guérin (BCG) vaccine, oral polio vaccine (OPV),
easles vaccine (MV) and diphtheria, tetanus and pertussis (DTP)
accine according to the immunization schedule recommended by
he World Health Organization (WHO). The coverage of children
ith these three vaccines reached the goal of 85% at provincial,
ounty, and township level in 1988, 1990, and 1995, respectively.
ases of tuberculosis, polio, measles, pertussis, diphtheria, and
etanus decreased by about 300 million, and an estimated 4 mil-
ion liveswere saved by the programover the 30 years following its
aunch [1]. TheWestern PaciﬁcRegionalOfﬁce (WPRO) of theWHO,
here China is located, certiﬁed China to be Polio-free in 2000.
here have been no reported cases of polio due to wild poliovirus
n China since 1994 [2].
Comparing data collected prior to the implementation of EPI,
he reported national measles morbidity and mortality rates have
eclined by more than 95% in 1990. The reported incidence of
easles dropped to a historically low level of 5/100,000/year in
995.The reported incidence of diphtheria decreased from 10 to
0/100,000/year in the 1950s to <0.01/100,000/year in the 1990s,
Abbreviations: AFP, Acute Flaccid Paralysis; BCG, Bacillus Calmette-Guérin;
CDC, Chinese Center for Disease Control and Prevention; DTP, diphtheria, tetanus
nd pertussis; EACIP, Experts Advisory Committee on Immunization Program; EPI,
xpanded Program on Immunization; HBV, hepatitis B vaccine; HBsAg, hepatitis
surface antigen; MV, measles vaccine; MOH, Ministry of Health; NIP, National
mmunization Program; NITAG, National Immunization Technical Advisory Group;
PV, oral polio vaccine; SIA, supplementary immunization activity;WPRO,Western
aciﬁc Regional Ofﬁce; WHO, World Health Organization.
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while pertussis decreased from 100 to 200/100,000/year dur-
ing the 1960–1970s to 0.37/100,000/year in 2004. The annual
number of reported cases of diphtheria and pertussis ranged
from 0 to 11 and 3000–6000, respectively, during 2003–2008
[1].
China integrated hepatitis B vaccine (HBV) into the national EPI
program in 2002. Following the implementation of the hepatitis
B immunization program, the hepatitis B surface antigen (HBsAg)
seroprevalence rate for the population aged 1–59 years declined
from 9.8% in 1992 to 7.2% in 2006, and for children age 1–4 years it
was 0.96% [3].
Overall, implementation of the national EPI has played an
important role in the protection of the population’s health, con-
tributing to increased average life expectancy and to the creation
of large economic and social beneﬁts. In 2007, China integrated
into thenational immunizationprogramvaccinesagainstmeningo-
coccal meningitis, Japanese encephalitis, hepatitis A, rubella and
mumps. These vaccines will play an important role in advancing
the control of these vaccine-preventable diseases.
China’s Experts Advisory Committee on Immunization Pro-
gram (EACIP) was established in 1982 and has evolved continually
since then throughout the implementation of EPI. It has become a
key technical advisory body and plays a vital role in formulating
national policy and providing technical guidance to EPI and other
immunization issues.
2. Structure and mechanism of the China EACIP
Open access under CC BY-NC-ND license. 2.1. The history of the China EACIP
China’s EACIP was established in August 1982 as a group of
experts under theCommittee onMedical Sciences of theMinistry of
Health (MOH). In June1988 theEACIPbecameaseparate committee
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pig. 1. The relationship between the Experts Advisory Committee on Immunization
rogram (EACIP), theMinistry ofHealth (MOH), theNational Immunization Program
NIP) and the Chinese Center for Disease Control and Prevention (CCDC).
onsistingof 26experts. InOctober1992andMarch1997, theChina
ACIP members were reelected and the membership expanded to
8 and 30 experts, respectively, appointed by the MOH. The latest
lection to the China EACIPwasmade inOctober 2004, as described
elow.
.2. Members and duty of the EACIP
The members of the EACIP are nominated and appointed by the
OH. Tenure is valid until reelection. The Chair and assistant Chairs
re similarly appointed although they serve in an honorary capac-
ty. From October 2004, the EACIP consisted of 33 members: one
hair, three assistant chairs, 26 members with expertise in speciﬁc
isciplines, and three secretaries. Membership selection criteria
nclude: expertise in research and development of vaccines, testing
nd approval of vaccines, pediatrics, infectious diseases, immunol-
gy, management of health policy, public health, epidemiology
nd statistics, ethics, and health law. In addition, consideration
s given to membership being representative of different regions
nd social and economic status. EACIP does not have any mem-
ers in observer status, and none of its members are ofﬁcers of the
OH.
The duties of the EACIP are wide ranging and include: formula-
ion and modiﬁcation of immunization regulation and strategies;
dvising theMOHon important strategies related to immunization;
onducting ﬁeld surveys and assessments to aid decision-making;
nd providing recommendations regarding personnel training and
cientiﬁc exchange under the leadership of the MOH.
.3. The main mechanism of EACIP activities
The China EACIP carries out its role to provide technical
dvice relevant to immunization under the leadership of the
OH. The Department of National Immunization Program (NIP)
f the Chinese Center for Disease Control and Prevention (CCDC)
s responsible for the routine secretarial work of the EACIP. Its
unctions include obtaining background documents and literature
ollection, data review, assisting theMOH to set the agenda, coordi-
ating meeting logistics, writing minutes, drafting reports, routine
ommunication with EACIP members, and other activities. Fig. 1
hows the relationship between EACIP, MOH and CCDC.
The EACIP carries out its activities through four differentmecha-
isms: (1) plenary meetings involving all members, which are held
nce annually and initiated by the MOH; (2) working group meet-
ngs involving only some of the EACIP members, which are held by
he MOH and the CCDC to resolve one or more speciﬁc technical
ssues; (3) correspondence meetings, which involve the circula-
ion of written papers and documents about issues that need to
e resolved with the collection of opinions of the EACIP experts;
nd (4) speciﬁc ﬁeld surveys and supervision,with relevant experts
articipating at the invitation of the MOH or the CCDC. During eachS (2010) A84–A87 A85
of these activities, members should avoid participating if there is
considered to be any obvious conﬂict of interest.
Currently there is no formal publication to disseminate the rec-
ommendations and decisions of the EACIP to the public, though
formal minutes are recorded and are available for all participants.
The EACIP submits its deliberations in the form of a proposal or
memorandum to the MOH or the CCDC. After due consideration,
the MOH or the CCDC will disseminate its policy or recommen-
dations as a formal technical guideline. The MOH and CCDC can
accept the entirety or just a part of the recommendations made by
the EACIP.
3. Role of the China EACIP
The main tasks of the EACIP are to advise on the national immu-
nization schedule, to participate in the drafting and review of
technical documents, and to provide resource persons in the ﬁeld
supervision and staff training for some speciﬁc activities.
3.1. An evidenced-based review to identify priority diseases for
vaccination and formulation of the immunization schedule
As noted earlier, China initiated the national EPI in 1978
with the introduction of universal infant vaccination with BCG,
OPV, MV and DTP vaccines. In 2002, China introduced hepati-
tis B vaccine into the national EPI. In 2007, vaccines against
rubella, mumps, meningococcal serotype A and A+C, Japanese
encephalitis, and hepatitis A were added to the routine schedule
. These changes resulted in an increased number of vaccines requir-
ing appropriate scheduling from both the programme logistics
and user perspective. In addition, other improvements were made
in the formulation, administration, and dosage of vaccines, e.g.,
monovalent measles vaccine was replaced by trivalent Measles-
Mumps-Rubella (MMR) vaccine, and DTP with whole cell pertussis
antigen was replaced by acellular DTaP vaccine. The national EPI
also expanded beyond children to include adults, with the poten-
tial for vaccines for haemorrhagic fever, leptospirosis, and anthrax
for speciﬁc high-risk populations. The China EACIP has played an
important role in the formulation and modiﬁcation of the immu-
nization schedule to accommodate vaccines it has recommended
previously.
In 1986, the EACIP suggested modiﬁcations to the immuniza-
tion schedule based on the scientiﬁc data and evidence to ensure
maintenance of high coverage, lower program costs, and fewer
vaccination visits by implementing more efﬁcient schedules that
combined multiple immunizations at the same visit.
In 2005, the EACIP recommended changes in the two-dose
immunization schedule for measles vaccine from 8 months and 7
years to 8months and 18months. At the same time a recommenda-
tionwasmade to increase the dose from0.2ml to 0.5ml to improve
vaccine effectiveness.
The signiﬁcant expansion of China’s immunization schedule in
2007 was based on a detailed review of the literature and available
evidence. The EACIP identiﬁed over 16,623 papers and documents
related to vaccines against measles, mumps, rubella, meningo-
coccal meningitis, Japanese encephalitis, and hepatitis A. Using a
systematic review process and meta-analysis, 1550 papers were
selected according to pre-deﬁned criteria, and 202 papers were
analyzed indetail (Table 1). Using thesedata theEACIP analyzed the
disease burden, epidemiologic characteristics, biological character-
istics of the target vaccines, and supply and availability of vaccines.
Data on disease associated morbidity, mortality, disability, socio-
economic distribution, and public health burden were analyzed to
facilitate prioritization of diseases and potential vaccines [4–7].
This evidenced-based exercise enabled the EACIP to recommend
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Table 1
Summary of meta-analyses of articles of relevance to the Expanded Immunization Program undertaken by China’s Experts Advisory Committee on Immunisation Program
in 2007.
Vaccine Potential papers identiﬁed Papers obtained
for review
Papers providing
information for inclusion
in recommendations
Outcome
Measles-Mumps-Rubella 2362 487 38 Integrated in EPI
Meningococcal meningitis 5706 368 51 Integrated in EPI
Japanese encephalitis 6590 453 46 Integrated in EPI
Hepatitis A 1965 242 67 Integrated in EPI
Total 16,623 1550 202
Table 2
China’s immunization schedule in 2007.
Vaccinea Age and dose number
Birth 1m 2m 3m 4m 5m 6m 8m 18m 2y 3y 4y 6 y
HepB 1 2 3
BCG 1
OPV 1 2 3 4
DPT 1 2 3 4
DT 1
MR (MV) 1
MMR (MM, MV) 1
JE-a 1 2
Men-A 1, 2b
Men A+C 1 2
HepA-a 1
JE-ic 1, 2d 3 4
HepA-ic 1 2
a BCG: Bacillus Calmette-Guérin; OPV: oral poliovirus vaccine; DPT: Diphtheria-Pertussis-Tetanus vaccine; DT: Diphtheria-Tetanus vaccine; MR(MV): Measles-Rubella
vaccine; MV: Measles vaccine; MMR: Measles-Mumps-Rubella vaccine; MM: Measles-Mumps vaccine; MV: measles vaccine; JE-a: Japanese encephalitis live attenuated
vaccine; Men-A: Group A meningococcal polysaccharide vaccine; Men A+C: Group A+C meningococcal polysaccharide vaccine; HepA-a: hepatitis A attenuated vaccine;
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•E-i: Japanese encephalitis inactivated vaccine; HepA-i: hepatitis A inactivated vacc
b Interval of 3 months between 1st and 2nd dose.
c Optional vaccine.
d Interval of 7–10 days between 1st and 2nd dose.
riority diseases and priority vaccines to be added to the immu-
ization schedule. The EACIP submitted these recommendations
o the MOH for consideration and further development of China’s
urrent immunization policy and immunization schedule (Table 2).
.2. Participation in drafting and review of technical documents
The EACIP presides over or participates in the drafting and
eview of technical guidelines and proposals related to immu-
ization policy, regulation, and disease control programs. Over
he years, a number of regulations and technical guidelines have
een disseminated by the MOH or the CCDC as formal docu-
ents. The public, physicians, and public health doctors can obtain
his information from the MOH (http://www.moh.gov.cn) and
CDC (http://www.chinacdc.net.cn) websites. The following sec-
ions list the documents developed and reviewed during recent
ears:
.2.1. Policies and regulations
Regulations on Management of Vaccine Circulation and Inocula-
tion (2005);
Regulations on Management of Vaccine Storage and Transporta-
tion (MOH and SFDA 2006);
Technical Appraisal on Adverse Events Following Immunization
(MOH, 2008).
.2.2. Working guidelines
Guideline of Immunization Technique (MOH, 2005).3.2.3. Disease control programs
• TheNational Plan of Action for the Elimination ofMeasles, During
the Years 2006–2012;
• The National Plan on Hepatitis B Prevention and Control During
the Years of 2006–2010;
• The National Plan of Action to Maintain China Polio-free During
the Years of 2003–2010.
3.2.4. Technical proposals
• Implementation Proposal on Expansion of the Expanded Program
for Immunization (MOH, 2007);
• Proposal for National Surveillance of Measles, Proposal for
National Surveillance of Neonatal Tetanus;
• Proposal for National Surveillance of Acute Flaccid Paralysis
(AFP);
• Proposal for National Surveillance of Routine Immunization Cov-
erage; Notice of School Entrance Checking (by MOH, MOE, 2005).
3.3. Organizing and participating in evaluation and supervision
The EACIP organized and participated in the national immu-
nization coverage reviews in 1988, 1991, and 1994, the national
EPI review in 2004, and the national hepatitis B sero-survey in
2006. EACIP experts play an important role in developing the
proposals for such surveys. The EACIP members also have pro-
vided ﬁeld supervision of supplemental immunization activities
(SIA), conﬁrmed and certiﬁed China’s polio-free status, and recom-
mended mass immunization programs, e.g., provision of hepatitis
A and Japanese encephalitis vaccine in earthquake-stricken areas
of Sichuan province in 2008 [8].
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.4. Staff training
When requested by the MOH or CCDC, the EACIP participates in
eveloping teaching materials and providing resource persons for
ifferent training activities organized by NIP/CCDC to strengthen
taff knowledge and capacity. For example the EACIP developed the
raining materials for expansion of EPI in 2008, and held national
raining courses delivered to 1299 trainers at the provincial and
refecture levels. In addition, training courses were held at the
rovincial, prefecture, county and township levels attended by
34,449 EPI staff.
. Future perspectives of the China EACIP
The China EACIP will continue to guide efforts for Chinese EPI
evelopment, such as formulatingmid-termor long-termdevelop-
ent programs, and developing mid-term and long-term working
riteria of theMOH’s Healthy China 2020 Plan. The EACIPwillmake
ecommendations for integrating new vaccines into EPI and the
evelopment of immunization strategies for non-EPI vaccines and
dult vaccination. It is also envisaged that the regular activities of
ACIP, such as the publication of the committee’s activities and
ther outcomes, together with mechanisms to enhance the inde-
endent functioning of the committee, will be improved.
. ConclusionThe EACIP has played and will continue to play an increasingly
mportant role in the progress and development of immuniza-
ion in China. Based on EACIP recommendations to enhance
mmunization activities, Chinahaswitnessed remarkable improve-
[S (2010) A84–A87 A87
ments in health outcomes. In is envisaged that the China EACIP
will continue to evolve with its members contributing through
their expertise, diligence and commitment to the health of the
population.
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